Complements OneSource ® Value-Added Service Offerings
BOSTON, MA -- November 29, 2005 -- PerkinElmer Inc. (NYSE: PKI), a global leader in Health Sciences today announced the acquisition of Biomatic, Inc., a leading provider of laboratory compliance and validation services for the pharmaceutical and biotechnology markets. Biomatic’s expertise in multi-vendor laboratory compliance and validation services will extend the comprehensive and global capabilities of PerkinElmer’s Laboratory Services business. Terms of the deal were not disclosed.
“We are pleased to combine Biomatic’s expertise with PerkinElmer’s broad set of laboratory services offerings to drive productivity and results for our customers,” said Dusty Tenney, vice president and general manager of PerkinElmer Laboratory Services. “Biomatic is a proven leader in helping pharmaceutical and biotechnology companies achieve and maintain laboratory compliance in drug discovery and development, and quality control labs. This combination positions us well to support the ever-changing service needs of our customers.”
Through this acquisition, PerkinElmer will complement its OneSource® asset management solution that consolidates all the essential maintenance, equipment management and lab productivity needs of pharmaceutical, biotechnology and academic research laboratories into a complete, regulatory compliant solution. OneSource provides dedicated on-site technical resources to improve service, quality, responsiveness and equipment uptime, by reducing costs through improved productivity.
“We are excited about this new opportunity to bring together our high-quality services offerings in the areas of laboratory compliance, validation, maintenance and asset management with PerkinElmer’s global service business,” said Dr. Joseph Tehrani, president, Biomatic, Inc., who will join PerkinElmer after the acquisition. “PerkinElmer is an established global leader in the health sciences arena and we are confident our complementary services will provide a winning combination for our customers and the marketplace.”
Factors Affecting Future Performance
This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share and revenue growth and other financial results, developments relating to our customers and end-markets, the planned divestiture of our Fluid Sciences business segment, and plans concerning business development opportunities. Words such as “believes,” “anticipates,” “plans,” “expects,” “projects,” “forecasts,” “will” and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management’s current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) our ability to consummate the sale of the Company’s aerospace and fluid testing businesses, including obtaining regulatory approvals; (2) our ability to identify a purchaser of the Company’s semiconductor business, negotiate and consummate the sale of such business, including obtaining regulatory approvals; (3) economic and geopolitical forces that may limit any continued or expected economic or end market strengthening or recoveries; (4) risks related to our failure to introduce new products in a timely manner; (5) the impact of our debt on our cash flow and investment opportunities; (6) our ability to comply with financial covenants contained in our credit agreements and our debt instruments; (7) a delay in resolution of the Company’s tax audits and an adverse determination with respect to the Company’s tax audits by the Internal Revenue Service or other taxing authorities; (8) cyclical downturns continuing to affect several of the industries into which we sell our products; (9) our ability to adjust our operations to address unexpected changes; (10) our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business; (11) the loss of any of our licenses that may require us to stop selling products or lose competitive advantage; (12) competition; (13) regulatory compliance; (14) regulatory changes; (15) our failure to obtain and enforce intellectual property protection; (16) our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets; (17) other factors which we describe under the caption “Forward-Looking Information and Factors Affecting Future Performance” in our most recent annual report on Form 10-K and in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Other Information
Health Sciences end markets include genetic screening, environmental, service, biopharma, and medical imaging. Photonics markets include sensors and specialty lighting.
About Biomatic Biomatic, Inc. provides innovative service solutions for the biotechnology, life sciences and chemical industries, including generation, implementation and management of client specific qualification and validation protocols and total quality systems for laboratory instrumentation, equipment and support infrastructure. The company’s technical expertise ensures equipment and laboratory infrastructure is competently de-commissioned, re-commissioned and re-validated so that scientists can focus on their core business needs.